Do you want to read an article? Please log in or register.
Conversion of FACIT-F to PROMIS® Fatigue Scores in Two Phase 3 Baricitinib Rheumatoid Arthritis Trials
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib
Arthritis Res Ther
Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, Germino R, Murray CW
doi: 10.1186/s13075-020-02324-7
Further Publications Rheumatology
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
Arthritis Res Ther
Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C
doi: 10.1186/s13075-021-02554-3
Rheumatoid Arthritis
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Ann Rheum Dis.
Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME
doi: 10.1136/
Rheumatoid Arthritis
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
Clin Rheumatol.
Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ
doi: 10.1007/s10067-018-4077-3.
Rheumatoid Arthritis
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
Arthritis Care Res (Hoboken).
Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV
doi: 10.1002/acr.23004.
Rheumatoid Arthritis
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Clin Rheumatol.
van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R
doi: 10.1007/s10067-018-4221-0.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Rheumatoid Arthritis
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
RMD Open.
Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M
doi: 10.1136/rmdopen-2016-000410.
Rheumatoid Arthritis
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Rheumatology (Oxford).
Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L
doi: 10.1093/rheumatology/kew329.